Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
instant pay day loans
Popular Articles
Teeth Whitening Products

Improved Recovery In Patients Who Exercised Prior To Stroke
A person who has exercised regularly prior to the onset of a stroke appears to recover more quickly, say researchers from Mayo Clinic in Florida, who led a national study.
generic viagra online
Luminex Receives FDA Clearance For An Update To The XTAG(R) Respiratory Viral Panel Package Insert
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared labeling updates for the company"s xTAG® Respiratory Viral Panel (RVP) to include data about the performance of the test in humans infected with the pandemic strain of influenza A, 2009 influenza A/H1N1, which is sometimes referred to as "swine flu." The test"s labeling has been updated to include information from two new studies that demonstrate that xTAG RVP can be an effective aid in the detection of 2009 Influenza A/HIN1, but cannot identify the hemagglutinin gene of the 2009 Influenza A/H1N1 in clinical specimens.
News of the day
Researchers Make Progress Toward Early Identification Of Muscular Dystrophy
The saying "Knowing is half the battle" is never more true than when discussing early treatment of disease. Muscular dystrophy is one such disease where patients can benefit from early treatment. Now, new research is moving doctors and scientists closer to disease diagnosis in advance of patient symptoms.
Diagnostics

Gendux Molecular Limited Withdraws Its Marketing Authorisation Application For Contusugene Ladenovec Gendux (contusugene Ladenovec)

The European Medicines Agency has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Contususgene ladenovec Gendux (contusugene ladenovec), suspension for injection. Contusugene ladenovec Gendux was expected to be used for the treatment of squamous cell carcinoma in head and neck cancer. The application for the marketing authorisation for Contususgene ladenovec Gendux was submitted to the Agency on 2 July 2008. At the time of withdrawal, it was under review by the Agency"s Committee for Medicinal Products for Human Use (CHMP). In its official letter, the company stated that the withdrawal of the application was based on the difficult financial situation of its parent company Introgen Therapeutics, Inc., which prohibits them to fund further activities related to this application. More information about Contusugene ladenovec Gendux and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website shortly. European Medicines Agency


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009